What is Esophageal Cancer?
Esophageal cancer forms in the esophagus — the tube that carries food from the throat down to the stomach. It is one of the more common digestive cancers in Asia. The cancer often doesn't cause obvious symptoms until it has already grown large, which is why checking high-risk individuals with an endoscopy early is very important.
the most common type in Asia; found in the middle and upper parts of the esophagus; strongly linked to smoking and heavy alcohol use
found in the lower esophagus; linked to chronic acid reflux (GERD) and a condition called Barrett's esophagus, where the lower esophagus lining changes in a way that raises cancer risk.
📌 Mahalaga: Ang paulit-ulit o lumalalang dysphagia (hirap lumunok) — lalo na kung may kasabay na pagbaba ng timbang — ay isang signal na kailangan agad na suriin ng doktor.
Causes and Risk Factors
Tobacco smoking, heavy alcohol use, drinking very hot beverages regularly, and poor nutrition
Chronic acid reflux (GERD), Barrett's esophagus (a pre-cancerous change in the lining of the lower esophagus), and obesity
Common Symptoms
- Dysphagia — difficulty swallowing that starts with solid foods and slowly gets worse to include soft foods and then liquids
- Rapid and significant weight loss — caused by not being able to eat enough due to worsening swallowing problems
- Chest pain or a feeling of pressure behind the breastbone
- Worsening heartburn or indigestion
- Coughing or hoarseness
- Food coming back up after swallowing (regurgitation)
Diagnosis & Prognosis
An upper GI endoscopy lets doctors look directly at the inside of the esophagus with a camera. The location of the tumor helps tell whether it is SCC (in the upper or middle part) or Adenocarcinoma (in the lower part) — which affects the choice of surgery and chemotherapy. A biopsy confirms the exact type, which determines the radiation and chemotherapy plan used at every stage.
EUS is the most accurate tool for measuring how deep the tumor has grown into the wall of the esophagus. Very early tumors (only on the surface — T1a) can sometimes be removed using the endoscope alone, without major surgery. Deeper tumors (T3–T4) usually need chemotherapy and radiation before surgery to shrink them first. EUS also checks nearby lymph nodes — if lymph nodes contain cancer, this strongly supports giving chemotherapy before surgery.
A CT scan checks the full body for cancer spread and helps determine if surgery is possible. Key findings include whether the tumor has grown into the aorta or nearby airways (which would make surgery too risky), whether the liver has any spots (the most common place for distant spread in lower esophageal cancer), and whether lymph nodes appear enlarged. If large lymph nodes are found, further testing may be needed to confirm whether surgery is still an option.
A PET-CT scan finds cancer cells that are still actively growing. It changes the treatment plan in about 15 to 20 out of 100 patients by finding small areas of spread that did not appear on CT — this helps avoid unnecessary surgery in those patients. It is also used after chemotherapy and radiation to see whether the cancer responded well.
For esophageal and lower esophageal junction (GEJ) adenocarcinoma, testing for HER2 is done on all tissue samples. About 20 out of 100 GEJ adenocarcinomas are HER2-positive — adding Trastuzumab to chemotherapy is the standard treatment for these patients. PD-L1 testing is also important: a score of 5 or higher means adding Pembrolizumab or Nivolumab to chemotherapy significantly improves survival. MSI-High tumors (about 5 out of 100) respond very well to Pembrolizumab alone.
Key factors: the type of cancer (Adenocarcinoma vs. SCC — they respond differently to radiation and immunotherapy), HER2 status, PD-L1 score, how deep the tumor has grown, whether lymph nodes are involved, whether the entire tumor was removed during surgery, how well the tumor responded to chemotherapy and radiation beforehand, and the patient's overall health.
Historically, esophageal cancer had poor outcomes because most cases were found late. Giving chemotherapy and radiation before surgery (the CROSS protocol) has significantly improved survival for patients with localized disease. Immunotherapy after surgery and for advanced disease is now standard.
Stage I: About 46 out of 100 people are still alive after 5 years. Stage II: 25 to 30 out of 100. Stage III: 15 to 18 out of 100. Stage IV: About 5 out of 100 — though patients with HER2-positive or high PD-L1 disease on modern targeted therapy or immunotherapy are doing significantly better.
Treatment Options
Surgery removes the tumor along with part of the esophagus and part of the stomach. Minimally invasive or Da Vinci robotic esophagectomy uses smaller cuts, which reduces surgical trauma and helps patients recover faster.
Chemotherapy (using drugs like carboplatin plus paclitaxel, or cisplatin plus 5-FU) given at the same time as radiation is the standard preparation before surgery. For patients who cannot have surgery, this combination is given as the full course of treatment.
For HER2-positive esophageal or GEJ adenocarcinoma, adding Trastuzumab to chemotherapy is the standard first-line treatment.
Nivolumab is approved as a treatment given after surgery and chemoradiation. Pembrolizumab and Nivolumab are also used as first-line treatments for advanced, PD-L1-positive esophageal cancer.
Esophageal cancer — particularly squamous cell carcinoma — is among the most common cancers in China. Jinshazhou Hospital offers minimally invasive esophagectomy, modern IMRT/VMAT radiotherapy, and full systemic therapy including immunotherapy.
Not sure which treatment applies to your case?
Get a personalised review from a Esophageal Cancer specialist.
Our partner oncologists at Jinshazhou Hospital review your scans and pathology report and return a detailed recommendation — typically within 72 hours, at no cost.
Staging & Symptoms by Stage
Esophageal cancer often develops very slowly. Patients unknowingly adjust their eating habits — chewing longer, avoiding hard foods — long before they realize swallowing has become difficult. By the time swallowing problems are obvious, the cancer is usually already at an advanced stage.
Usually no symptoms. Some patients notice occasional mild chest discomfort or a very slight sense that dry or dense foods (like bread or meat) move more slowly when swallowed. Mild long-standing heartburn may be present.
Difficulty swallowing begins — first with solid foods like meat or bread, then gradually with softer foods. Mild chest or back discomfort, a feeling that food is getting stuck, and mild unintentional weight loss may appear.
Swallowing becomes harder — even soft foods and liquids are difficult. There is persistent chest or back pain, food coming back up, chronic cough (especially after eating), hoarseness, and significant weight loss (often 5 to 10 kilograms). Food or saliva sometimes enters the lungs instead of the stomach.
Cancer has spread to the liver, lungs, or bones. The patient may be unable to swallow even liquids. There is severe weight loss, muscle wasting, a persistent cough, bone pain, yellowing of the skin, trouble breathing, and extreme tiredness. Many patients need a feeding tube.
📌 Mahalaga: Difficulty swallowing — even if it seems minor — always needs an endoscopy. This symptom almost always has a serious cause, and finding it early greatly improves the outcome.
What to Do If You Notice Symptoms
Noticing possible symptoms can be frightening — but taking the right steps quickly can dramatically change the outcome. Most symptoms are caused by non-cancerous conditions, but only a doctor can tell for sure.
⚠️ Go to the ER immediately if you experience: severe difficulty breathing, heavy uncontrollable bleeding, sudden severe pain, loss of consciousness, or stroke-like symptoms (facial drooping, one-sided weakness, slurred speech).
Note what you feel, when it started, how often it happens, and what makes it better or worse. List all medications you take and any family history of cancer.
Don't wait for symptoms to go away on their own. Persistent symptoms lasting more than 2–3 weeks always need medical evaluation.
Ask your doctor which tests they are ordering and why. Request a physical copy of every result. If a biopsy is needed, ask about molecular and genetic testing on the tissue sample.
- Don't rush into treatment. Take 1–2 weeks to gather information and a second opinion before committing to a plan.
- Request an MDT review. The best outcomes come from cases reviewed by surgeons, oncologists, radiation specialists, and pathologists together.
- Always get a second opinion. A second opinion is standard practice, not an insult to your doctor.
- Ask about clinical trials. They often give access to treatments not yet widely available locally.
The Cost of Waiting
Most people don't delay treatment out of carelessness. They delay because life is busy, symptoms seem minor, and fear makes it easier to wait. But with esophageal cancer, every month of delay has a measurable cost — financial, physical, and personal.
A symptom appears — unusual fatigue, a persistent change, something that wasn't there before. It's easy to dismiss. "I'll wait and see if it goes away."
The symptom hasn't resolved. Life is busy. The thought of a diagnosis is frightening. Another month passes.
Pain, weight loss, or visible changes force the issue. A doctor is finally seen. Initial tests begin — but results take weeks, and the referral chain adds more time.
The esophageal cancer has spread beyond its original site. Surgery alone is no longer sufficient. The plan now involves multiple treatments running together — and the goal shifts from cure to control.
Multiple chemotherapy lines. Targeted therapy. Repeat hospitalizations. Extended leave from work. The financial burden compounds every month treatment continues — with no clear end date.
The Financial Reality
Realistic cost ranges based on standard oncology care pathways in the Philippines and abroad. Actual costs vary by hospital, regimen, and stage.
- Primary treatmentSurgery + adjuvant chemo or radiation
- Duration4–6 months
- Hospitalizations1–2 planned admissions
- Work impact3–6 months leave
- 5-year survival70–90%
- Primary treatmentMultiple chemo lines + targeted therapy
- Duration12–36+ months, ongoing
- HospitalizationsMultiple unplanned admissions
- Work impact12+ months or permanent
- 5-year survival10–30%
💡 Why the gap is so large: Early-stage esophageal cancer often needs one treatment (surgery). Late-stage needs several running at once — and when one stops working, another line begins. Costs multiply, and they don't stop.
The financial weight of cancer treatment can feel overwhelming — but it rarely has to be borne by one person. The people in your life — family, friends, community — love you, and most of them would do anything to help if they only knew what you were going through. Let them in. Share what you are facing. You may be surprised how quickly people rally when someone they care about needs them. A diagnosis is not a burden to hide — it is an invitation for the people who matter most to show up for you.
Why Patients Choose Jinshazhou Hospital of GZUCM
Most Filipino patients with esophageal cancer eventually discover that the treatments with the best outcomes — NanoKnife (IRE) for inoperable tumors, CyberKnife SBRT for sub-millimetre precision radiotherapy, proton therapy, CAR-T cell therapy, and comprehensive molecular profiling — are either unavailable in the Philippines or require months-long waiting lists. Jinshazhou Hospital of Guangzhou University of Chinese Medicine offers all of these under one roof, with every case reviewed by a standing multi-disciplinary team before a single treatment is recommended. The cost is typically 50–70% less than Singapore, 60–75% less than Thailand, and up to 90% less than the United States — for the same technologies and international-standard care. See the full technology and treatment overview →
Detection & Treatment Timing — Outcome Matrix
Four possible journeys for a esophageal cancer patient. Detection timing and treatment timing are independent decisions — and each combination produces a measurably different outcome.
Detection
Cancer caught before it spreads. One curative treatment course, short duration. Most patients return to normal life within 6–12 months.
Detected early but treatment was delayed — fear, denial, or access issues. The cancer advanced despite the early window. Outcomes worsen with every month of delay.
Detection
Found at an advanced stage but treatment started immediately. Multiple modalities required. High cost, prolonged treatment, but prompt action improves the odds.
Cancer found late and treatment further delayed. The highest financial burden combined with the lowest chance of long-term survival. Treatment focuses on control, not cure.
Patients treated at Stage I or II typically complete treatment in months — not years. They keep their hair, their energy, their routines. They return to work. They attend their children's graduations, their grandchildren's birthdays. Treatment becomes a chapter in their life, not the whole story.
Advanced treatment today can extend life by months — sometimes years. That time is not a consolation prize. It is the Sunday lunches, the long conversations, the slow mornings you didn't think you'd have. Every day gained is a day with the people who matter most.
Any of us can be taken without warning. But a diagnosis, as frightening as it is, offers something most people never receive: the chance to be intentional — to choose how you spend your time, to say what you've been meaning to say, to be fully present with the people you love most. That clarity is worth something. Don't let it pass without acting on it.
Cancer does not pause. Every week of delay is a week the disease uses to grow, to spread, to make treatment harder and options fewer. What is treatable today may not be operable in three months. What is curable this year may only be manageable next year. The window exists — but it will not stay open. The single most powerful thing you can do right now is pick up the phone and start the conversation. Everything else follows from that one decision.
Ready to explore your options for Esophageal Cancer?
Submit your case and a specialist coordinator will connect you with the right oncologist at Jinshazhou Hospital — free, and with no obligation.